LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 134

Search options

  1. Article: Vaccinations in Selected Immune-Related Diseases Treated with Biological Drugs and JAK Inhibitors-Literature Review and Statement of Experts from Polish Dermatological Society.

    Narbutt, Joanna / Żuber, Zbigniew / Lesiak, Aleksandra / Bień, Natalia / Szepietowski, Jacek C

    Vaccines

    2024  Volume 12, Issue 1

    Abstract: The growing use of biological drugs in immune-mediated chronic diseases has undoubtedly revolutionized their treatment. Yet, the topic of vaccinations in this group of patients still raises many concerns and implies many therapeutic problems that require ...

    Abstract The growing use of biological drugs in immune-mediated chronic diseases has undoubtedly revolutionized their treatment. Yet, the topic of vaccinations in this group of patients still raises many concerns and implies many therapeutic problems that require discussion and standardization of management. The aim of this literature review is to present current knowledge regarding safety and efficacy of vaccinations in dermatological and rheumatological patients treated with biological drugs and JAK inhibitors. Additionally, this article provides recommendation from experts of the Polish Dermatological Society about proper use of vaccinations during therapy with biologics. Generally, all live attenuated vaccines are contraindicated during immunosuppressive/immunomodulatory therapy. If there is need, they should be administered long enough prior to the therapy or after cessation. Yet, inactivated vaccines mostly can be safely used, but the problem in this case is the effectiveness of the vaccination. Most studies report that the immune response in patients on biologics after administration of different inactivated vaccines is similar to or even better than in the control group. Thus, the importance of vaccination among patients on biologics must be emphasized to reduce omissions and the fear of possible side effects or insufficient post-vaccination response.
    Language English
    Publishing date 2024-01-13
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines12010082
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability.

    Narbutt, Joanna / Niedźwiedź, Michał / Lesiak, Aleksandra / Ceryn, Justyna / Skibińska, Małgorzata

    Patient preference and adherence

    2023  Volume 17, Page(s) 421–431

    Abstract: Psoriasis (PsO) is a chronic, systemic, immune-mediated inflammatory skin disease affecting 1% to 5% population worldwide. In one-third of patients, the first symptoms of PsO manifest in childhood, with a mean age of nine years. Psoriasis in children ... ...

    Abstract Psoriasis (PsO) is a chronic, systemic, immune-mediated inflammatory skin disease affecting 1% to 5% population worldwide. In one-third of patients, the first symptoms of PsO manifest in childhood, with a mean age of nine years. Psoriasis in children under 16 years of age constitutes 4% of dermatological problems in this age group. Chronic inflammation of the skin observed in PsO is associated with a development of potentially serious comorbidities, including psoriatic arthritis, hypertension, metabolic syndrome, cardiovascular diseases, inflammatory bowel disease, depression and anxiety. It is reported that among children with psoriasis between 5 and 16 years of age health-related quality of life is reduced by 30.5%. Early diagnosis and effective treatment are crucial in pediatric psoriatic patients to avoid future complications and stigmatization. Treatment for psoriasis consists of a range of topical medications, phototherapy and non-biologic and biologic systemic therapies. Approved biologics for PsO in pediatric patients include etanercept, adalimumab, ustekinumab, ixekizumab and secukinumab. Secukinumab, a recombinant, fully human monoclonal antibody targeting IL-17A, was approved by the EMA (2020) and FDA (2021) in pediatric patients above 6 years of age for the treatment of moderate to severe plaque psoriasis who are candidates for systemic therapy. This review discusses the selection and acceptability of secukinumab in children with psoriasis.
    Language English
    Publishing date 2023-02-16
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2455848-5
    ISSN 1177-889X
    ISSN 1177-889X
    DOI 10.2147/PPA.S350753
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Successful treatment of a child's generalized pustular psoriasis with adalimumab in combination with low-dose acitretin.

    Arasiewicz, Hubert / Lesiak, Aleksandra / Dec, Michał / Lesniak-Jakubiec, Lilianna

    Postepy dermatologii i alergologii

    2023  Volume 40, Issue 3, Page(s) 464–466

    Language English
    Publishing date 2023-07-16
    Publishing country Poland
    Document type Journal Article
    ZDB-ID 2596142-1
    ISSN 1642-395X
    ISSN 1642-395X
    DOI 10.5114/ada.2023.128984
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Enoxaparin-induced eruptive angiokeratomas.

    Niedźwiedź, Michał / Żebrowska, Agnieszka / Lesiak, Aleksandra / Narbutt, Joanna / Skibińska, Małgorzata

    Polish archives of internal medicine

    2023  Volume 133, Issue 5

    MeSH term(s) Humans ; Angiokeratoma/chemically induced ; Enoxaparin/adverse effects ; Skin Neoplasms
    Chemical Substances Enoxaparin
    Language English
    Publishing date 2023-03-14
    Publishing country Poland
    Document type Journal Article
    ZDB-ID 123500-x
    ISSN 1897-9483 ; 0032-3772
    ISSN (online) 1897-9483
    ISSN 0032-3772
    DOI 10.20452/pamw.16463
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 360: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Off-label medications in the treatment of hospitalized children with atopic dermatitis.

    Niedźwiedź, Michał / Skibińska, Małgorzata / Narbutt, Joanna / Lesiak, Aleksandra

    Postepy dermatologii i alergologii

    2022  Volume 40, Issue 1, Page(s) 72–77

    Abstract: Introduction: Off-label prescribing is defined as using medications outside conditions of the marketing authorisation including their licensed indications, dosage, age and route. Atopic dermatitis (AD) is the most common chronic skin condition in ... ...

    Abstract Introduction: Off-label prescribing is defined as using medications outside conditions of the marketing authorisation including their licensed indications, dosage, age and route. Atopic dermatitis (AD) is the most common chronic skin condition in children which can be related to a high level of off-label prescribing.
    Aim: To investigate the frequency of off-label prescribing and the medications involved in relation to indications and age in paediatric patients hospitalized for atopic dermatitis in a paediatric dermatology ward in 2019.
    Material and methods: One hundred and seventy-five consecutive discharge letters of patients were analysed regarding gender, age and medications used during hospital stay and prescribed on discharge. Each medication was checked against the licensed age and indications.
    Results: Altogether 564 medications were prescribed, including 289 topical and 275 systemic ones with 278 prescribed off-label (49.1%). Out of 289 topical medications, 113 (39.1%) were prescribed off-label regarding indications and 34 (11.76%) regarding the age of the patients. In the systemic medications group, 96 (34.53%) were prescribed off-label as AD was not a registered indication and 35 (12.73%) as the age of the patients was outside the marketing authorization. The most frequent medications prescribed off-label were antihistamines, antibiotics and corticosteroids.
    Conclusions: Prescribing off-label in paediatric population is a common practice. Both topical and systemic medications are frequently used in AD patients off-label, therefore doctors should be familiar with the pitfalls of prescribing beyond the licensed indications and age.
    Language English
    Publishing date 2022-10-10
    Publishing country Poland
    Document type Journal Article
    ZDB-ID 2596142-1
    ISSN 1642-395X
    ISSN 1642-395X
    DOI 10.5114/ada.2022.119967
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: The role of inflammasomes in cutaneous pathology.

    Ciążyńska, Magdalena / Narbutt, Joanna / Skibińska, Małgorzata / Lesiak, Aleksandra

    Postepy dermatologii i alergologii

    2022  Volume 39, Issue 1, Page(s) 39–46

    Abstract: Inflammasomes are large intracellular multiprotein complexes, which constitute a novel part of the innate immune system. In response to danger signals from pathogens or other harmful agents, inflammasomes assemble resulting in production of the ... ...

    Abstract Inflammasomes are large intracellular multiprotein complexes, which constitute a novel part of the innate immune system. In response to danger signals from pathogens or other harmful agents, inflammasomes assemble resulting in production of the inflammatory cytokines. We discuss recent knowledge of the role of deregulated inflammasome activity in skin pathologies such as autoinflammatory diseases as well as common skin diseases such as psoriasis and atopic dermatitis. We also present an insight into the activation and effector mechanisms of inflammasomes in skin carcinogenesis. The complex influence of inflammasome on cutaneous disorders raises new challenges and opportunities for the treatment of skin diseases.
    Language English
    Publishing date 2022-02-28
    Publishing country Poland
    Document type Journal Article ; Review
    ZDB-ID 2596142-1
    ISSN 1642-395X
    ISSN 1642-395X
    DOI 10.5114/ada.2022.113802
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Blue Light in Dermatology.

    Sadowska, Magdalena / Narbutt, Joanna / Lesiak, Aleksandra

    Life (Basel, Switzerland)

    2021  Volume 11, Issue 7

    Abstract: Phototherapy is an important method of dermatological treatments. Ultraviolet (280-400 nm) therapy is of great importance; however, there are concerns of its long-term use, as it can lead to skin aging and carcinogenesis. This review aims to evaluate the ...

    Abstract Phototherapy is an important method of dermatological treatments. Ultraviolet (280-400 nm) therapy is of great importance; however, there are concerns of its long-term use, as it can lead to skin aging and carcinogenesis. This review aims to evaluate the role and the mechanism of action of blue light (400-500 nm), a UV-free method. The main mediators of cellular responses to blue light are nitric oxide (NO) and reactive oxygen species (ROS). However, the detailed mechanism is still not fully understood. It was demonstrated that blue light induces an anti-inflammatory and antiproliferative effect; thus, it may be beneficial for hyperproliferative and chronic inflammatory skin diseases such as atopic dermatitis, eczema, and psoriasis. It was also found that blue light might cause the reduction of itching. It may be beneficial on hair growth and may be used in the treatment of acne vulgaris by reducing follicular colonization of
    Language English
    Publishing date 2021-07-08
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662250-6
    ISSN 2075-1729
    ISSN 2075-1729
    DOI 10.3390/life11070670
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Prospective 3-month study on the efficacy of UV-free blue light in mild psoriasis vulgaris treatment.

    Lesiak, Aleksandra / Bednarski, Igor A / Narbutt, Joanna

    Postepy dermatologii i alergologii

    2021  Volume 38, Issue 3, Page(s) 446–449

    Abstract: Introduction: Psoriasis is one of the most common chronic skin diseases affecting up to 2% of the general population. In recent years, an important direction for the development of treatment for psoriasis has been the use of blue light emitted by LED ... ...

    Abstract Introduction: Psoriasis is one of the most common chronic skin diseases affecting up to 2% of the general population. In recent years, an important direction for the development of treatment for psoriasis has been the use of blue light emitted by LED lamps.
    Aim: To evaluate the efficacy of blue-light emitting device in psoriasis vulgaris treatment.
    Material and methods: The study involved 30 adults with a mild form of psoriasis vulgaris not previously receiving biological treatment and other forms of phototherapy. Participants of the study used a device emitting blue LED light for 3 months. Each participant received a device for use at home, with which he/she exposed 2 psoriatic lesions located on the limbs. Before and after the study, the severity of the disease was evaluated using PASI, DLQI and LPSI.
    Results: During 3 months of the therapy, a statistically significant decrease in the mean LPSI (in both treated locations) and DLQI was noted (LPSI decrease from 5.25 ±1.82 to 1.98 ±1.74,
    Conclusions: Our results confirm that phototherapy using blue LED light is both a safe and highly effective way to treat psoriasis.
    Language English
    Publishing date 2021-07-26
    Publishing country Poland
    Document type Journal Article
    ZDB-ID 2596142-1
    ISSN 1642-395X
    ISSN 1642-395X
    DOI 10.5114/ada.2021.107931
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Impact of the COVID-19 Pandemic on Atopic Dermatitis Patients.

    Sieniawska, Joanna / Lesiak, Aleksandra / Ciążyński, Karol / Narbutt, Joanna / Ciążyńska, Magdalena

    International journal of environmental research and public health

    2022  Volume 19, Issue 3

    Abstract: Atopic dermatitis (AD) can have a significantly negative impact on quality of life (QoL). The impact of coronavirus disease 2019 (COVID-19) on the AD population is not yet well established. The study comprised 195 patients with diagnosed AD who were ... ...

    Abstract Atopic dermatitis (AD) can have a significantly negative impact on quality of life (QoL). The impact of coronavirus disease 2019 (COVID-19) on the AD population is not yet well established. The study comprised 195 patients with diagnosed AD who were asked about their cognitive and preventive behaviors regarding COVID-19 and the accessibility of medical support, including online consultations. Moreover, the patients responded to the self-reported Dermatology Life Quality Index (DLQI) and Hospital Anxiety and Depression Scale (HADS). Most of the patients were worried about being infected with COVID-19. Most of the patients believed that people suffering from skin disease were more prone to be infected with COVID-19 compared with the general population. Most the patients negatively assessed the availability of dermatological treatment during the pandemic. Furthermore, 66.1% of the patients declared using telemedicine. Nearly 50% of patients were discontented with telemedicine, and 1/3 of the patients did not mind the use of telemedicine. AD during the COVID-19 pandemic was associated with a lower overall health rating and life satisfaction and impaired QoL related to mental health in a Polish population. These results provide original information that can be applied in dermatologic patient screenings to evaluate the state of depression and anxiety during the epidemic period.
    MeSH term(s) COVID-19 ; Dermatitis, Atopic/epidemiology ; Humans ; Pandemics ; Quality of Life ; SARS-CoV-2 ; Severity of Illness Index
    Language English
    Publishing date 2022-02-02
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2175195-X
    ISSN 1660-4601 ; 1661-7827
    ISSN (online) 1660-4601
    ISSN 1661-7827
    DOI 10.3390/ijerph19031734
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Yellowish nodular changes in infants - juvenile xanthogranuloma and xanthoma.

    Hołdrowicz, Agnieszka / Narbutt, Joanna / Lesiak, Aleksandra

    Postepy dermatologii i alergologii

    2021  Volume 38, Issue 2, Page(s) 159–162

    Language English
    Publishing date 2021-03-10
    Publishing country Poland
    Document type Journal Article
    ZDB-ID 2596142-1
    ISSN 1642-395X
    ISSN 1642-395X
    DOI 10.5114/ada.2021.104292
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top